Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
NCT ID: NCT06375473
Last Updated: 2026-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3000 participants
OBSERVATIONAL
2024-04-19
2027-04-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer
NCT06387810
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
NCT06700603
Irinotecan Liposome in Combination With Capecitabine
NCT06578052
Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
NCT05074589
Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma
NCT06485739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Perioperative cohort
Irinotecan liposome II combination therapy regimen for perioperative patients
Irinotecan liposome II combination therapy regimen
Irinotecan liposome II combination therapy regimen
First line cohort
Irinotecan liposome II combination therapy regimen for first line advanced patients
No interventions assigned to this group
Second line cohort
Irinotecan liposome II combination therapy regimen for second line advanced patients
No interventions assigned to this group
Late stage third line and above cohort
Irinotecan liposome II combination therapy regimen for third line and above advanced patients
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Irinotecan liposome II combination therapy regimen
Irinotecan liposome II combination therapy regimen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18 years old, male or female;
* Patients receiving treatment based on irinotecan hydrochloride liposome injection II;
* The subjects voluntarily joined the study and signed the informed consent.
Exclusion Criteria
* The researchers determined that other conditions were not suitable for inclusion in the study.
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Taiping Zhang, doctor
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital, Beijing, China
Liwei Wang, doctor
Role: PRINCIPAL_INVESTIGATOR
Renji Hospital, Shanghai, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Peking Unicersity First Hospital
Beijing, , China
Henan Provincial People's Hospital
Henan, , China
Ningbo Medical Center Lihuili Hospital
Ningbo, , China
Fudan University Shanghai Cancer Center
Shanghai, , China
Renji，Hospital
Shanghai, , China
Wuhan Union Hospital of China
Wuhan, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xu Jin
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA-PC-RWS-011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.